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Abstract
Exosomes are naturally occurring nanosized vesicles that have attracted considerable attention as 
drug delivery vehicles in the past few years. Exosomes are comprised of natural lipid bilayers with 
the abundance of adhesive proteins that readily interact with cellular membranes. We posit that 
exosomes secreted by monocytes and macrophages can provide an unprecedented opportunity to 
avoid entrapment in mononuclear phagocytes (as a part of the host immune system), and at the 
same time enhance delivery of incorporated drugs to target cells ultimately increasing drug 
therapeutic efficacy. In light of this, we developed a new exosomal-based delivery system for a 
potent antioxidant, catalase, to treat Parkinson’s disease (PD). Catalase was loaded into exosomes 
ex vivo using different methods: the incubation at room temperature, permeabilization with 
saponin, freeze-thaw cycles, sonication, or extrusion. The size of the obtained catalase-loaded 
exosomes (exoCAT) was in the range of 100 - 200 nm. A reformation of exosomes upon 
sonication and extrusion, or permeabilization with saponin resulted in high loading efficiency, 
sustained release, and catalase preservation against proteases degradation. Exosomes were readily 
taken up by neuronal cells in vitro. A considerable amount of exosomes was detected in PD mouse 
brain following intranasal administration. ExoCAT provided significant neuroprotective effects in 
in vitro and in vivo models of PD. Overall, exosome-based catalase formulations have a potential 
to be a versatile strategy to treat inflammatory and neurodegenerative disorders.
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1. INTRODUCTION
Parkinson’s disease (PD) is one of the fastest growing neurological disorders in the 
developed world. The expected increase in lifespan of the population will further lead to a 
rise in age-related diseases, including neurodegenerative disorders. PD is known to be 
associated with brain inflammation, microglia activation and secretory neurotoxic activities, 
including reactive oxygen species (ROS) [1-4]. Samples from PD brains have shown 
reduced levels of redox enzymes, catalase and superoxide dismutase, and other antioxidants 
[5-7]. This may cause oxidative stress and neurodegeneration in PD patients. In this regard, 
catalase is one of the most potent in nature antioxidant that deactivates one million free 
radicals per second per molecule catalase in a cycle of catalytic reaction. As such, a 
successful brain delivery of catalase may be instrumental for PD therapy.
Regrettably, the blood brain barrier (BBB) severely limits transport of this large protein. In 
fact, 98% of all potent drugs that may improve therapy of various diseases of central 
nervious system (CNS) are not in clinic because of their inability to cross the BBB [8]. 
Different drug nanoformulations have been developed to overcome the BBB [9, 10]. 
Unfortunately, the opsonization of drug-loaded nanoparticles in the bloodstream caused two 
main problems of drug nanoformulations: nanotoxicity and rapid drug clearance by 
mononuclear phagocyte system (MPS) [11]. To solve this problem, a polyethyleneglycol 
(PEG) corona was introduced to perpetuate a stealth effect. However, although the 
PEGylation decreased drug uptake by MPS, it concurrently reduced the interaction with 
target and barrier cells, thus, decreasing drugs biodistribution, particularly, in the brain 
[12-14]. In addition, the development of immune response to PEG corona significantly 
increased clearance of PEGylated drug nanocarriers [15-17]. For example, PEGylated 
liposomes were reported to lose their long-circulating property on the second week 
following systemic administration in mice [17]. This may become a real problem in case of 
chronic disease conditions, such as PD that requires a prolonged drug treatment. 
Furthermore, it was reported that 22%-25% healthy blood donors already have pre-existing 
PEG antibodies due to the everyday exposure to PEG in cosmetics, food, etc [18, 19]. In this 
respect, several reports indicated that exosomes may have an immune privileged status that 
can efficiently decrease drug clearance [20-22]. Thus, exosome-based nanocarriers may 
function as an “invisibility cloak” for incorporated therapeutic agents; they can diminish 
clearance by MPS, and at the same time increase drug transport to the brain.
Regarding their nature, exosomes are nanosized vesicles secreted by a variety of cells [23], 
in particular, cells of the immune system: dendritic cells [24], macrophages [25], B cells 
[26], and T cells [27]. Exosomes were initially thought to be a mechanism for removing 
unneeded proteins. Recent studies revealed, they are actually specialized in long-distance 
intercellular communications facilitating transfer of proteins [28], functional mRNAs and 
microRNAs for subsequent protein expression in target cells [29, 30]. To shuttle their cargo, 
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exosomes can attach by a range of surface adhesion proteins and specific vector ligands 
(tetraspanins, integrins, CD11b and CD18 receptors), and deliver their payload to target cells 
[24, 31]. Noteworthy, exosomes possess an intrinsic ability to cross biological barriers. 
Thus, tumor-derived exosomes and microvesicles originated in the brain of glioma-bearing 
mice, and human glioblastoma patients were detected in the blood circulation indicating 
their ability to cross the BBB [32].
Exosomes were exploited as drug delivery vehicles in several investigations [33-37]. In 
particular, exosomes loaded with an anti-inflammatory low molecular drug, curcumin, were 
shown to protect mice from lipopolysaccharides-induced brain inflammation [36]. 
Moreover, exosomes were harnessed for systemic delivery of exogenous siRNA across the 
biological barriers [20, 33, 37-39]. The incorporation of the therapeutic agents into 
exosomes increased the circulation time, preserved drug therapeutic activity, and improved 
the brain delivery. The similar methodology was applied to polymer nanoparticles that were 
covered with erythrocytes membranes [40]. Sheltering of nanoparticles with cellular 
membranes/lipids produced a potent stealth effect increasing their time circulation in the 
blood. Furthermore, cellular membranes of monocytes and macrophages were utilized to 
manufacture nanovesicles by their serial extrusion through filters with diminishing pore 
sizes [41]. According to this report, cell-derived nanovesicles loaded with anticancer agent, 
doxorubicin (Dox) significantly reduced tumor growth in mice without adverse effects that 
were reported for equipotent free Dox. Noteworthy, the effects of Dox-loaded exosomes 
were superior than the commercially available Dox-loaded liposomes, Doxil; the liposomal 
formulation was inefficient in reducing tumor growth in this model [41]. Noteworthy, 
exosomes can exert unique biological activity reflective of their origin. According to a 
recent study, exosomes released from mesenchymal stem cells produced significant cardio-
protective paracrine effects against myocardial ischemia/reperfusion injury even without any 
drug loaded [42]. Overall, these reports indicate that exosomes may function as exceptional 
vehicles for the delivery of therapeutic agents.
We demonstrated earlier that macrophages preloaded with nanoformulated catalase, or 
transfected with catalase-encoded plasmid DNA can release exosomes with incorporated 
catalase, and facilitate drug transfer to target cells of neurovascular unit: neurons, astrocytes, 
and brain microvessel endothelial cells [43-45]. This process resulted in profound 
therapeutic effects in mouse models of PD [44, 46]. We report here the development of a 
new exosomal-based formulation of catalase (exoCAT) that was obtained by drug loading 
into naïve exosomes ex vivo. Different approaches for drug incorporation were validated: 
incubation at room temperature (RT) with or without saponin permeabilization, freeze-thaw 
cycles, sonication, or extrusion of exosomes in the presence of catalase. The obtained 
exoCAT formulations were evaluated for catalase loading efficiency, release and antioxidant 
activity. Selected optimal exoCAT efficiently decreased oxidative stress and increased 
neuronal survival in in vitro and in vivo models of PD. We hypothesized that the 
encapsulation of catalase into exosomes may preserve catalase enzymatic activity, prolong 
blood circulation time, and reduce immunogenicity, thereby improve drug therapeutic 
efficacy. Importantly, this technology may be more generally applicable to the treatment of 
many CNS diseases, in particular neurodegenerative disorders [47-49] such as PD, 
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Alzheimer’s disease, infectious diseases (meningitis, encephalitis, and HIV-associated 
neurocognitive disorders [50, 51]), stroke [52, 53], and lysosomal storage diseases [54, 55].
2. MATERIALS AND METHODS
2.1. Reagents
Catalase from bovine liver was purchased from Calbiochem (San Diego, CA). A lipophilic 
fluorescent dyes, 1,1'-dioctadecyl-3,3,3',3'-tetramethylindo-carbocyanine perchlorate (DIL), 
and 2-(5-(1,3-dihydro-3,3-dimethyl-1-octadecyl-2H-indol-2-ylidene)-1,3-pentadienyl)-3,3-
dimethyl-1-octadecyl-perchlorate (DID) were purchased from Invitrogen (Carlsbad, CA, 
USA). 6-hydroxydopamine (6-OHDA), lipopolysaccharides (LPS), rhodamine 
isothiocyanate (RITC), and Triton X-100 were obtained from Sigma-Aldrich (St. Louis, 
MO, USA). Interferon gamma (INT-γ) was purchased from Peprotech Inc. (RockyHill, NJ, 
USA).
2.2. Cells
A mouse macrophage cell line (Raw 264.7) was purchased from American Type Culture 
Collection (ATCC, Manassas, VA, USA, cat # TIB-71), and cultured in Dulbecco’s 
Modified Eagle’s Media (DMEM) (Invitrogen) supplemented with 10% (v/v) heat-
inactivated fetal bovine serum (FBS). Neuronal PC12 rat adrenal pheochromocytoma cell 
line was obtained from ATCC, and cultured in Dulbecco’s modified Eagle medium 
(Hyclone, South Logan, UT, USA) supplemented with 10 % FBS, and 1 % (v/v) of both 
penicillin and streptomycin. The cells were grown in an incubator with optimal culture 
conditions of 37 °C and 5% CO2, and the medium was routinely replaced every 2–3 days.
Bone marrow derived macrophages (BMM) were obtained by differentiation of bone 
marrow stem cells extracted from murine femurs (C57BL/6, female mice) as described in 
[56]. The cells were cultured for 10 days in media supplemented with 1000 U/mL 
macrophage colony-stimulating factor (MCSF). The purity of monocyte culture was 
determined by flow cytometry using FACS Calibur (BD Biosciences, San Jose, CA, USA). 
Mouse primary cultured cortical neurons and dopaminergic (DA) neurons from substantia 
nigra pars compacta (SNpc) were isolated from mouse pups cortex and midbrain as 
described [57].
2.3. Isolation of exosomes
Concomitant media from Raw 264.7 macrophages grown on 75T flasks (20 × 106 cells/
flask) was collected, and exosomes were isolated using gradient centrifugation [24]. In brief, 
the culture supernatants were cleared of cell debris and large vesicles by sequential 
centrifugation at 300g for 10 min, 1000g for 20 min, and 10,000g for 30 min, followed by 
filtration using 0.2 μm syringe filters. Then, the cleared sample was spun at 100,000g for 
one hour to pellet the exosomes, and supernatant was collected. The collected exosomes 
(1011 – 1012 exosomes/flask) were washed twice with phosphate buffer solution (PBS). To 
avoid contamination by the FBS-derived exosomes, FBS was spun at 100,000g for 2 hours 
to remove exosomes before the experiment. The recovery of exosomes was estimated by 
measuring the protein concentration using the Bradford assay and by Nanoparticle Tracking 
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Analysis (NTA). The obtained exosomal fraction was re-suspended in PBS (500 µl, 1 
mg/mL total protein), and characterized for size and polydispersity.
2.4. Loading of Exosomes
Four approaches for catalase incorporation into exosomes were evaluated: the incubation at 
RT with or without saponin (Method I), freeze-thaw cycles (Method II), sonication (Method 
III), and extrusion (Method VI). For Method I, naive exosomes released from Raw 264.7 
macrophages were diluted in PBS to a concentration 0.15 mg/mL of total protein, then 
catalase solution in PBS (0.5 mg/mL) was added to 250 µl of exosomes to the final 
concentration 0.1 mg/mL total protein, and incubated at RT for 18 hours. In case of a 
saponin treatment, a mixture of catalase and exosomes was supplemented with 0.2% saponin 
and placed on shaker for 20 min at RT. For Method II, the catalase solution was added to 
exosomes as described above, incubated for 30 min, then rapidly freezed at −80° C, and 
thawed at RT. The freeze-thaw cycle was repeated three times. For Method III, the catalase 
mixture with exosomes was sonicated (500 v, 2 kHz, 20% power, 6 cycles by 4 sec pulse /2 
sec pause), cooled down on ice for 2 min, and then sonicated again using Qsonica Sonicator 
Q700 (Fisher Scientific, Hampton, NH, USA). For Method IV, catalase mixture with 
exosomes was extruded (x10 times) through Avanti Lipids extruder (Avanti Polar lipids 
Inc., Alabaster, AL, USA) with 200 nm-pores diameter. Loaded with catalase exosomes 
were purified from free catalase by gel-filtration chromatography with Sepharose 6 BCL 
(Sigma-Aldrich).
2.5. Characterization of different exoCAT formulations by (Dynamic Light Scattering) DLS, 
(Atomic Force Microscopy) AFM, Nanoparticle Tracking Analysis (NTA), and Hyperspectral 
microscopy
The effective hydrodynamic diameter of empty exosomes, or exosomes loaded with catalase 
was measured by DLS using the ZetaPlus’ Zeta Potential Analyzer (Brookhaven 
Instruments, Santa Barbara, CA, USA) equipped with a 35 mW solid state laser (658 nm 
laser) as described in [58, 59]. The size, distribution, and number of particles for various 
exosomal formulations were also examined by NTA. For this purpose, exoCAT 
formulations were prepared at concentration 0.01 mg/mL, and evaluated using NanoSight 
500, Version 2.2 (Wiltshire, United Kingdom). The morphology of exoCAT aggregates was 
investigated by AFM. Different exoCAT formulations were prepared in 50 mM phosphate 
buffer, pH 7.4 at total protein 10 µg/mL. A drop of the sample was placed on a glass slide, 
and dried under an argon flow. The AFM imaging was operated as described earlier [60].
ExoCAT formulations were further characterized by Hyperspectral microscopy (CytoViva 
Inc., Auburn, AL, USA). The hyperspectral images and the corresponding hyperspectral 
data were captured using an Olympus BX43 research grade optical microscope equipped 
with the patented CytoViva advanced dark field illumination system and diffraction grating 
hyperspectral imaging system (CytoViva Inc.). A 100x oil iris .6-1.30 NA objective was 
utilized. For the mean spectral comparison, data was captured from multiple pixels within 
multiple exosome particle areas of each sample. The mean spectrum from each sample was 
calculated using the CytoViva customized ENVI Hyperspectral Image Analysis software.
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2.6. Manufacture of gold nanoparticles and imaging of nanoparticle-loaded exosomes by 
Transmission Electron Microscopy (TEM)
Gold nanoparticles were prepared by mixing of 25 mL HAuCl4 (0.5 mM) TRIS solution 
(pH 10) with 25 mL Pluronic block copolymer F127 (10 mM) solution. The mixture was 
incubated at 55°C for 2 hours and the obtained nanoparticles were separated by centrifugal 
filtration at 1500 RPM using a filter with 100 kDa cut off. Effective hydrodynamic diameter 
and zeta-potential of gold nanoparticles were measured by photon correlation spectroscopy 
using ‘ZetaPlus’ Zeta Potential Analyzer (Brookhaven Instruments). The average diameter 
was 10.3 ± 0.2 nm, the polydispersity index (PDI) value was 0.06 ± 0.002 nm. For TEM 
evaluations, a drop of isolated exosomal fraction with incorporated by sonication gold 
nanoparticles was placed on Formvar®-coated copper grid (150 mesh, Ted Pella Inc., 
Redding, CA, USA). The dried grid containing exosomes were stained with vanadyl sulfate 
and visualized using a Philips 201 transmission electron microscope (Philips/FEI Inc., 
Briarcliff Manor, NY, USA).
2.7. Poly(lactic-co-glycolic acid) (PLGA) particles preparation
PLGA nanoparticles were prepared by modification of a w/o/w double emulsion method 
[61]. Briefly, 3.2 mL of 5% polyvinyl alcohol (PVA) was added to 100 mL of dH2O2 to 
form a w/o emulsion. In parallel, 0.35g PLGA polymer was dissolved in 3 mL 
dichloromethane, and 2 μmol DIL was added to the solution. After vigorous stirring, the 
PLGA emulsion was injected into 50 mL of 5% PVA solution under stirring (1500 rpm, at 
4°C) to form a primary w/o/w double emulsion. Then, the double emulsion was poured into 
500 mL of deionized water and maintained at 4°C. In order to evaporate the organic solvent, 
the temperature was slowly increased up to 20°C during two hours. The resulting 
nanoparticles were centrifuged for 30 minutes at 4000 g, washed with deionized water, and 
lyophilized. The average particle size measured by Malteasizer DLS was 317.5 + 1.94 nm 
with PDI of 0.113.
2.8. Preparation of liposomes
Liposomes were prepared by reverse phase evaporation method. Briefly 2 mg of 
phospholipids (95 molar % of phosphatidyl choline and 5% of PEG-PE) were dissolved in 6 
ml of chloroform: diisopropyl ether 1:1 mixture. Then 1 ml of 5 mM calcein solution in PBS 
filtered through 450 nm syringe filter was added to the mixture. Mixture was intensively 
vortexed and bath sonicated to form stable emulsion. Organic solvents were evaporated on 
rotary evaporator forming the liposome aqueous dispersion. 200-250 µl of Millipore water 
can be added at this point to the mixture in case some part of water was also evaporated. 
Evaporation was continued to get almost clear dispersion. Then volume was adjusted to 
1000 µl by addition of small amount of water. Dispersion was vortexed and bath sonicated 
to get clear solution. Liposomes were sequentially extruded 21 times through 200 nm 
polycarbonate filters using a hand extruder (Avanti). Liposomes were purified through a 
Sepharose CL4B column to remove not encapsulated fluorophore. Volume of the sample 
was doubled after column separation. Calcein loaded liposomes were used within 24 h after 
column separation.
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2.9. Western blot analysis
Western blot technique was applied to evaluate loading efficiency for different exoCAT 
formulations. Protein concentrations were determined using BCA kit (Pierce Biotechnology, 
Rockford, IL, USA). The catalase protein bands were detected with primary rabbit 
polyclonal anti-catalase antibodies (Santa Cruse, CA, USA; 1:200 dilution), and secondary 
horseradish peroxidase (HRP)-conjugated goat anti-rabbit Ig-HRP (Santa Cruse; 1:2500 
dilution). The protein bands were visualized by chemiluminescent substrate (Pierce 
Biotechnology) and quantitated using ImageJ software (NIH, Bethesda, MA, USA) [62]. To 
correct for loading differences, the levels of proteins were normalized to the constitutively 
expressed in exosomes TSG101 protein. The TSG101 levels were visualized by TSG101 
monoclonal antibodies, Abcam (Cambridge, MA, USA).
2.10. Enzymatic activity of catalase loaded into exosomes
The loading efficiency for different exoCAT formulations was assessed by catalase 
enzymatic activity using hydrogen peroxide decomposition assay [60]. For this purpose, 
different exoCAT formulations were incubated with pronase (0.1 - 0.2 mg/mL) for 3 hours 
at 37° C. Following the incubation, the aliquots were subjected for catalytic activity 
assessment as described above. The same assay was used to examine the preservation of 
catalase enzymatic activity in exosomes against proteases degradation. Stability of catalase 
was expressed in the residual activity vs. initial activity of catalase.
2.11. Exosomal uptake in PC12 cells
PC12 neuronal cells is a common model for in vitro evaluation of drug neuroporotective 
effects [63]. Exosomes (230 µg total protein/mL) were subjected to various procedures 
(incubation at RT, freeze/thaw cycles, or sonication), and then stained with DIL (2 µmol). 
PC12 cells were seeded into 96-well plate (50,000 cell/well), cultured for three days, and 
then incubated with different DIL-labeled exoCAT for various times. Following the 
incubation, the cells were washed three times with ice-cold PBS, and solubilized in Triton 
X100 (1%). Fluorescence in each sample was measured by Shimadzu RF5000 fluorescent 
spectrophotometer (λex = 540 nm, λem = 565 nm). The amount of exosomes accumulated in 
neuronal cells was normalized for the total protein content and expressed as a number of 
exosomes per mg of the protein as means ± S.E.M. (n = 8). All exoCAT formulations were 
prepared at the same level of fluorescence, and a separate calibration curve was used for 
each exoCAT formulation.
2.12. In vitro confocal microscopy studies
Raw 264.7 macrophages (20 × 106 cells/flask) were cultured for three days in DMEM 
supplemented with 10% FBS, then concomitant media was collected, and exosomes were 
isolated by gradient centrifugation as described above. The isolated exosomes (100 µg/mL 
total protein) were sonicated, labeled with DIL (2 µmol), and incubated with PC12 cells 
grown on chamber slides (1 × 105 cells/chamber) for various time intervals [64]. Following 
the incubation period, the cells were washed, fixed, and stained with rabbit anti-PGP9.5 
antibodies (green, Abcam, #10404, 1:500 dilution) for actin micro-filaments, and a 
fluorescent stain, 4',6-diamidino-2-phenylindole (DAPI) for nuclei prior to the imaging. 
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Accumulation of fluorescently-labeled exosomes was visualized by a confocal fluorescence 
microscopic system ACAS-570 (Meridian Instruments, Okimos, MI, USA) with argon ion 
laser (excitation wavelength, 488 nm) and corresponding filter set. Digital images were 
obtained using the CCD camera (Photometrics).
2.13. Amplex Red dye fluorescence assay
Raw 264.7 macrophages seeded in 96-well plates (0.1 × 106 cells/well) were stimulated with 
INF-γ (2 µg/mL) and LPS (200 ng/mL) for 4 hours to induce ROS production. Non-
activated cells were used as controls. ExoCAT obtained by sonication in Krebs-Ringer 
buffer (145 mM NaCl, 4.86 mM KCl, 5.5 mM glucose, 5.7 mM NaH2PO4, 0.54 mM CaCl2, 
1.22 mM MgCl2, pH 7.4) were supplemented with Amplex Red Dye stock solution (10 
U/mL HRP and 10 mM Amplex Red), added to the activated macrophages, and the 
decomposition of ROS was measured by fluorescence at λex = 563 nm, λem = 587 nm as 
described [62]. The effect of the same amount of empty exosomes (1.4 × 1011/mL 
exosomes), or catalase alone (3,652 U/mL) on ROS decomposition was evaluated in the 
control experiments.
2.14. Cell viability assay
The protection of PC12 cell by exoCAT prepared by sonication was assessed by MTT assay. 
For this purpose, PC12 cells (1×105 cells/mL) were seeded into a 96-well plate and allowed 
to attach overnight. Then, the cells were exposed to 200 µM 6-OHDA and different exoCAT 
formulations, or catalase alone, or empty exosomes for four hours. Following the incubation, 
the cells were washed 3 times with ice-cold PBS, and incubated with the corresponding 
exoCAT formulations, or catalase alone, or empty exosomes for another 24 hours. 
Following the treatment, 20 µL MTT (5 mg/mL) was added into each well. After 3 hours of 
incubation at 37° C, the medium containing MTT was removed; and100 µL DMSO was 
added into each well to dissolve the purple MTT formazan. Absorbances were read at λ = 
570 nm by a microplate reader, and cell viability was expressed as a percentage of viable 
cells in the treated groups compared to the untreated control group.
2.15. Animals
C57BL/6 female mice (Charles River Laboratories, Durham, NC, USA) eight weeks of age 
were treated in strict accordance with the recommendations in the Guide for the Care and 
Use of Laboratory Animals of the National Institutes of Health. The protocol was approved 
by the Committee on the Ethics of Animal Experiments of the University of North Carolina 
at Chapel Hill. All surgery was performed under sodium pentobarbital anesthesia, and all 
efforts were made to minimize suffering. The animals were kept five per cage with an air 
filter cover under light-(12-hours light/dark cycle) and temperature-controlled (22 ± 1° C) 
environment. All manipulations with the animals were performed under a sterilized laminar 
hood. Food and water were given ad libitum.
2.16. Biodistribution of exosomes in mouse brain with inflammation
C57BL/6 mice (n = 4) were stereotactically injected with 6-OHDA solution (10 μg 6-OHDA 
in 0.9% NaCL with 0.02% ascorbic acid), flow rate of 0.1 μL/min into the striatum (AP: 
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+0.5; L: −2.0 and DV: −3.0 mm) [65]. Twenty one days later (at the peak of inflammation), 
mice were intranasally (i.n.) or intravenously (i.v.) injected with fluorescently-labeled 
exosomes (2.4 ×1010 exosomes/mouse). Four hours later, mice were sacrificed, perfused, 
and the brain slides were examined by confocal microscopy. 6-OHDA-intoxicated mice 
injected with PBS were used as controls. Nuclei were labeled with DAPI. To examine, 
which type of cells accumulates exosomes in the brain, a co-localization study with cell-
specific markers was carried out. For this purpose, the brain slides were co-stained with: 
primary (1) rabbit polyclonal antibodies to neurons, AntiNeuN (ab128886, Abcam, 1:500 
dilution), or (2) anti-tyrosine hydroxylase (TH) rabbit antibodies to TH-neurons 
(Calbiochem, 1:1000 dilution), or (3) rabbit anti CD146 to endothelial cells (ab75769, 
Abcam, 1:250 dilution), or (4) rabbit anti-GFAP antibodies to astrocyte marker (ab7260, 
Abcam, 1:500 dilution), and secondary antibodies, donkey anti-rabbit IgG H&L Alexa 555 
(abcam ab150074, Abcam, 1:500dilution). All slides were permeabilized for 60 min in 0.1M 
citrate buffer pH6.0 and 0.05% Tween 20, washed 3x 5min with 0.05% Tween 20 in PBS, 
blocked for 30 minutes with PBS and 5% Normal Donkey Serum+0.05% Tween 20, and 
stained with primary antibody at stated dilution overnight at 4C. Following the incubation, 
slides were washed 3x 5minutes/wash in PBS/Tween, and stained with secondary antibodies 
for one hour at room temperature. Then, the slides were washed 3x PBS/Tween 5min/wash 
ddH2O, and covered using Vectashield Hardset mounting media with Dapi. The images 
were examined by a confocal fluorescence microscopic system ACAS-570 and 
corresponding filter set.
2.17. Immunohistochemical and stereological analyses
6-OHDA-intoxicated mice (n = 7) were treated via i.n. administration with PBS, or catalase 
alone (1.2 × 109 exosomes with 408.44 U catalase/mouse × 2 in 10 µl PBS, ten times every 
other day), or exoCAT loaded by sonication or saponin permeabilization with the same 
amount of catalase (1.2 × 109 exosomes/mouse × 2 in 10 µl PBS), or the same amount of 
empty exosomes 48 hours after the intoxication (10 times every other day). Two control 
groups of healthy non-intoxicated animals were i.c. injected with PBS, and then 48 hours 
later were i.n. injected with PBS, or empty exosomes. Twenty one days later, animals were 
sacrificed, perfused; brains were removed, washed, post-fixed, and immunohistochemical 
analysis was performed in 30 µm thick consecutive coronal brain sections as described [46]. 
For the detection of microglia activation, tissue sections were incubated with primary 
monoclonal rat anti-mouse anti-CD11b antibodies (1:500 dilution), and secondary 
biotinylated goat anti-rat antibodies (Vector Laboratories, Burlingame, CA, 1:200 dilution). 
Thus, activated microglia within the SNpc will exhibit a more amoeboid morphology with 
sent out branches, compared to ramified barely visible resting microglia. In addition, levels 
of astrocytosis were assessed in the ventral midbrain region by fluorescent analysis of glial 
fibrillary acidic protein (GFAP) expression. For the GFAP staining, tissue sections were 
permeabilized with 0.01% Triton X-100 in TBS for 30 minutes and blocked for 1 hour with 
10% normal goat serum (NGS, Vector Laboratories Inc., Burlingame, CA), then incubated 
with rabbit anti-GFAP primary polyclonal antibodies ab7260 (AbCam, Cambridge, MA) 
1:100 dilution for 16 hours at 4°C. Tissue slides were incubated with goat anti-rabbit Alexa 
Fluor 647 secondary antibodies (Invitrogen; 1:200 dilution) for 1 hour, and mounted on 
slides. Immunoreactivity was evaluated by fluorescent analysis using confocal microscope 
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Zeiss 510 Meta Confocal Laser Scanning Microscope (Jena, Germany), and ImageJ software 
(NIH, Bethesda, MA, USA). For the assessment of neuroprotective effects, a TH staining 
was used to quantitate numbers of DA neurons [66]. The total number of TH-positive DA 
neurons was counted by using the optical fractionator module in StereoInvestigator software 
(MicroBrightField, Inc., Williston, VT) [46].
2.18. Apomorphine Test
C57BL/6 mice were i.c. injected with 6-OHDA (n = 7). Healthy mice i.c. injected with PBS 
were used as a control [67]. Starting from 48 hours after intoxication, mice were i.n. injected 
with PBS, or exoCAT obtained by saponin permeabilization every other day for two weeks. 
Twenty one days later, the animals were injected with apomorphine (0.05 mg ⁄ kg, s.c.) and 
rotations were scored every 10 min for 90 min as described [68].
2.18. Statistical analysis
For the all experiments, data are presented as the mean ± S.E.M. Tests for significant 
differences between the groups were performed using a t-test or one-way ANOVA with 
multiple comparisons (Fisher's pairwise comparisons) using GraphPad Prism 5.0 (GraphPad 
software, San Diego, CA, USA). A minimum p value of 0.05 was chosen as the significance 
level.
3. RESULTS
3.1. Manufacture of exosomal formulations of catalase (exoCAT)
Catalase was incorporated into exosomes using different methods: a) incubation at RT with 
or without of saponin permeabilization; b) freeze/thaw cycles; c) sonication, and d) 
extrusion procedures. The last two methods were utilized to cause a reformation/
deformation of exosomes in the presence of catalase. The obtained exoCAT formulations 
were purified from non-incorporated catalase by a gel-filtration chromatography with 
Sepharose 6BCL as described in Materials and Methods section.
According to the western blot analysis, the amount of catalase loaded into exosomes 
increased in the row: the incubation at RT < freeze/thaw cycle < sonication ≅ extrusion 
(Fig. 1 A). These results were confirmed by catalytic activity of the enzyme (Fig. 1 B). 
ExoCAT obtained by sonication and extrusion showed the highest catalytic activity, 
followed by exoCAT obtained by freeze/thaw cycles, and then the incubation at RT (without 
saponin permeabilization). The incubation of catalase with exosomes at RT resulted in the 
lowest loading efficiency (4.9 ± 0.5%, n = 4) among all evaluated methods. Nevertheless, 
when exosomes were permeabilized with saponin, catalase loading efficiency significantly 
increased (18.5 ± 1.3 %, p < 0.05). Furthermore, sonication and extrusion procedures 
resulted in the most efficient enzyme incorporation (26.1 ± 1.2 % and 22.2 ± 3.1%, 
respectively). We hypothesized that a formation of transient pores or even reformation of 
exosomes upon sonication and extrusion allowed diffusion of catalase from the surrounding 
media into exosomes. The freeze/thaw cycles technique gave somewhat intermediate values 
of loading efficiency (14.7 ± 1.1 %). Regarding the yield of the catalase formulations, about 
98% of exosomes were recovered upon all loading methods. Noteworthy, catalase structure 
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was stabilized upon incorporation into exosomes. No loss of catalase enzymatic activity was 
detected in exoCAT upon sonication, while catalase alone was significantly deactivated in 
the same conditions (down to 14%).
The release of catalase from pre-loaded exosomes was evaluated by enzymatic activity using 
dialysis membranes with a cut off 2000 KDa (Fig. 1 C). The fastest release was observed for 
the formulation obtained by incubation at RT without saponin (Fig. 1 C). In contrast, a 
prolonged and sustained release was recorded for exoCAT obtained by sonication; less than 
40% of catalase was released over 24 hours. Taken together, the sonication of exosomes in 
the presence of catalase resulted in the high loading efficiency, and sustained release of 
enzymatically-active catalase. In particular, each mg of exoCAT obtained by sonication 
contained approximately 1,376 ± 64.1 U of catalase activity in 4×1011 exosomes/mL.
3.2. Characterization of exoCAT formulations
The size of catalase-loaded exosomes was determined by DLS and NTA techniques (Table 
1). Particles of naked catalase showed small size (9.5 nm) with low polydispersity index 
(PdI), which was close to the theoretical diameter (10.5 nm) of a single protein globule 
calculated from the molecular mass of the enzyme [69]. An average diameter of empty 
exosomes was around 100 nm with a relatively high polydispersity (Table 1). The 
incubation of catalase with exosomes at RT (with or without saponin) did not significantly 
alter their size. However, freeze/thaw cycles, extrusion, and sonication of exosomes resulted 
in the significant size increases, especially, in the presence of catalase (Table 1). Overall, 
both DLS and NTA analyses indicate the size of the obtained exoCAT formulations was in 
the range of 100 - 200 nm. This suggests that the relatively small catalase-loaded 
nanoparticles might enter the target cells by endocytosis. We will investigate the 
intracellular trafficking of exoCAT in our further studies.
Based on the data from NTA experiments and evaluations of catalase activity, about 940 ± 
15 catalase molecules per exosome were incorporated by sonication. Noteworthy, exosomal 
formulations were stable at RT over a week; no changes in size and/or catalase activity were 
recorded. Furthermore, the restitution of lyophilized exoCAT in water solutions did not alter 
the size, and activity of exosomal formulations.
The AFM images revealed considerable differences in the morphology of exoCAT 
formulations (Fig. 1 D). Naïve exosomes isolated from Raw 264.7 macrophages, as well as 
exosomes incubated with catalase at RT, or obtained by extrusion procedures have a round 
morphology. Particles of exoCAT formulation manufactured by freeze-thaw cycle were 
considerably larger in size consisting of several dozen of smaller exosomes, probably due to 
the aggregation. The AFM images of sonicated exoCAT demonstrated non-spherical 
associates with a variety of shapes (Fig. 1 D).
Next, the loading of catalase into exosomes was confirmed by Hyperspectral microscopy. 
This technique enables optical observation, spectral characterization, and mapping of 
nanoscale materials in a wide range of biological and material-based environments. 
Supplemental Fig. S1 shows representative hyperspectral images of exosomes loaded with 
catalase by sonication (Fig. S1 A), and empty exosomes sonicated at the same conditions 
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(Fig. S1 B). The measurements illustrate a narrowing of the spectral response of the loaded 
versus the unloaded exosomes (Fig. S1 C). This suggests that significant alterations/
perturbations occur upon catalase incorporation into exosomes. The incorporation of 
catalase into exosomes significantly improved its enzymatic stability against protease 
degradation (Fig. 2). In accordance with the loading efficiency (Fig. 1 A-B), and release 
kinetics (Fig. 1 C), the stability of catalase was increased in the row: incubation at RT 
without saponin < freeze/thaw cycles < sonication (Fig. 2). Altogether, this indicates that 
catalase was not only associated with the surface of exosome, but was also incorporated into 
them.
3.3. Accumulation and therapeutic efficacy of exoCAT in target neuronal cells in vitro
The ability of nanocarriers to deliver the drug payload into target cells is crucial for the 
therapeutic efficiency of exosomal formulations. First, we examined, whether manipulations 
with exosomes affect their transport into target cells in vitro. Exosomes were subjected to 
various loading procedures (incubation at RT, freeze/thaw cycles, or sonication), labeled 
with lipophilic fluorescent dye, DIL, and then incubated with PC12 cells. Striking 
differences in accumulation levels were recorded (Fig. 3 A). In spite of their large size, 
sonicated exosomes were taken up at considerably greater levels than those subjected to 
freeze/thaw cycles, or incubation at RT. This suggests superior interactions of sonicated 
exosomes than other exosomal preparations with cellular plasma membranes. We speculate 
that a reorganization of exosomes upon sonication may result in the exposure of 
hydrophobic parts of the cellular lipid bilayers or incorporated proteins that improve their 
interactions with plasma membranes of target cells. Next, confocal images confirmed a 
profound accumulation of sonicated DIL-labeled exosomes in PC12 cells (Fig. 3 B). The 
exosomes were efficiently internalized into neurons followed 3-hour incubation (Fig. 3 B-I), 
filled the entire neuronal body and build up on the plasma membranes at later time points 
(Fig. 3 B-II). The unparalleled accumulation of exosomes in target cells was even more 
evident in comparison with the considerably lower uptake of commonly used for the drug 
delivery polymer-based PLGA nanoparticles (100 nm, Fig. 3 B-III), or liposomes (Fig. 3 B-
IV) that were applied at the same level of fluorescence. These nanocarriers (PLGA 
nanoparticles and liposomes) were utilized for the brain delivery of L-DOPA to treat PD 
[70, 71].
Given the efficient accumulation of exosomes in PC12 neurons, we hypothesized that 
exosomes with incorporated catalase may deliver a substantial amount of the enzyme into 
target neuronal cells, and as a result, provide a superior neuro-protective activity against 
oxidative stress. To test this hypothesis, the effect of exoCAT formulations on neuronal 
survival was evaluated in PC12 cells pre-treated with 6-OHDA to recapitulate components 
of PD neurodegeneration in vitro. Following the 6-OHDA pre-treatment, the PC12 cells 
were supplemented with various exoCAT formulations, and the neuronal survival was 
evaluated by MTT test (Fig. 3 C). As expected, exoCAT prepared by sonication and 
extrusion demonstrated greater neuroprotective activity than exosomes loaded with catalase 
by freeze/thaw cycles or incubation at RT, probably, due to the facilitated exoCAT 
accumulation, and/or protection of catalase against degradation in exosomal carriers. 
Noteworthy, permeabilization of exosomes by saponin upon loading with catalase 
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significantly increased neuroprotection effect produced by this formulation (Fig. 3 C). 
Catalase alone, as well as empty exosomes did not protect PC12 cells at these experimental 
conditions.
Next, exoCAT obtained by sonication was evaluated for the ability to eliminate ROS 
produced by activated macrophages in vitro (Fig. 3 D). In this experiment, macrophages 
pre-incubated with a mixture of LPS (100 ng/mL) and TNF-α (100 ng/mL) were utilized as 
a model of activated microglia in the PD brain. The activation of macrophages resulted in 
the significant increase in ROS production, whereas the addition of exoCAT considerably 
decreased hydrogen peroxide levels (Fig. 3 D). Interesting, empty exosomes also decreased 
ROS levels in activated macrophages down to the levels of the control non-activated cells, 
although this effect was less significant than the effect of exoCAT. This indicates that 
exosomes by themselves (probably, their internal content) have a capacity to deactivate free 
radicals. This result is consistent with the studies demonstrating protection effects of 
exosomes against myocardial ischemia/reperfusion injury [42]. Altogether, these data 
suggests that exoCAT can be a useful tool for ROS deactivation and neuronal protection 
against oxidative stress.
3.4. Transport of exosomes into mouse brain with inflammation
To visualize the ability of exosomes to target and deliver their payload to inflamed brain 
tissues, confocal imaging studies were conducted in a PD mouse model. To induce brain 
inflammation, C57BL/6 mice were intracranially (i.c.) injected with 6-OHDA into SNpc. 
Twenty one days later (at the pick of inflammation), mice were injected with DIL-labeled 
exosomes (2.4 × 1010 exosomes /20 µL/mouse) through intranasal (i.n.) (Fig. 4 B), or 
intravenous (i.v.) (Fig. 4 C) routs. Mice i.n. injected with PBS were used as controls (Fig. 4 
D). Four hours later, mice were euthanized, perfused, and brain slides were examined by 
confocal microscopy. Nuclei were stained with DAPI (blue). The images revealed a wide 
distribution of exosomes throughout the brain, in particular, cerebral frontal cortex, central 
sulcus, and cerebellum (Fig. 4 A). The amount of exosomes delivered upon the i.n. 
administration was greater (Fig. 4 B) than those delivered through i.v. injection (Fig. 4 C). 
Confocal images showed diffuse fluorescent staining throughout the brain tissues along with 
the stained vesicular compartments localized predominantly in perinuclear regions (shown 
by arrows). No fluorescence was found in control mice with the PBS injection (Fig. 4 D). As 
such, i.n. route of administration was selected for the further evaluations of exoCAT 
therapeutic effects.
3.5. Catalase-loaded exosomes protect SNpc neurons against oxidative stress in mice with 
acute brain inflammation
The neuropathology of PD includes brain inflammation, microglial activation, and secretion 
of neurotoxins, such as ROS, all of which contribute to neurodegeneration and degradation 
of motor function [72]. We posit that the successful brain delivery of catalase will reduce 
neuroinflammation resulting in improved disease outcomes. For this purpose, C57BL/6 mice 
were stereotactically injected with 6-OHDA into SNpc, and 48 hours later, mice were i.n. 
injected with exoCAT (1.2 × 109 exosomes with catalase activity 408.44 U/ 10 µL/ mouse 
into each nostril, 10 times every other day), or the same amount of catalase alone. Two 
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exoCAT formulations were evaluated; catalase-loaded exosomes by sonication, or 
permeabilization with saponin at RT (n = 7). Mice intoxicated with 6-OHDA, and then i.n. 
injected with PBS were used as control animals with brain inflammation (PD mice). Non-
intoxicated animals i.c. injected with PBS were used as healthy controls. To evaluate the 
effect of empty exosomes in healthy brain, another control group of healthy animals was i.c. 
injected with PBS, and then empty exosomes. Twenty-one days following administration of 
the test formulation, the mice were sacrificed, perfused with paraformaldehide (PFA), and 
brains harvested. Brain slides were stained with antibodies to activated microglia (Fig. 5), 
astrocytes (Supplemental Fig. S2), or TH-expressing DA neurons (Fig. 6). The 
quantification of the obtained results for anti-inflammatory and neuroprotective effects is 
presented on Fig. 5F and 6F, respectively.
6-OHDA injections produced substantial brain inflammation signified by up-regulated 
expression of CD11b by microglia within the SNpc that exhibited a more amoeboid 
morphology (Fig. 5 C) than ramified microglia in PBS-treated mice (Fig. 5 A). Furthermore, 
the 6-OHDA-mediated intoxication resulted in the complete degeneration of DA neurons in 
the ipsilateral hemisphere SNpc (Fig. 6 C, arrow). The anti-inflammatory effect of exoCAT 
was demonstrated by the significant (p < 0.005) reduction in microgliosis as measured by 
CD11b expression (Fig. 5 D, E, G) and decrease in astrocytosis as demonstrated by GFAP 
levels (Supplemental Fig. S2). Furthermore, i.n. administration of exoCAT resulted in a 3-
fold increase in survived DA neurons (Fig. 6 D, E, G) compared to the control 6-OHDA-
treated mice injected with PBS (Fig. 6 C, G). The neuroprotection was greater in the animal 
group treated with exoCAT obtained by permeabilization with saponin (Fig. 6 E, G) than 
with exoCAT loaded by sonication (Fig. 6 D, G). Not surprisingly, free catalase was not 
effective in decreasing inflammation or providing neuroprotection in 6-OHDA-intoxicated 
mice (Fig. 5 E and 6 E).
Next, we investigated the effect of exoCAT formulation obtained by saponin 
permeabilization in apomorphine test. Mice intoxicated with 6-OHDA and treated i.n. with 
PBS showed 150 ± 11 rotations per minute. In contrast, mice intoxicated with 6-OHDA and 
then treated i.n. with exoCAT as described above have significantly less rotations (26.1 ± 
3.1 per minute). Noteworthy, non-intoxicated healthy controls did not rotate at all.
Finally, we investigated possible toxic effect of exosomal carriers alone. No effect of empty 
exosomes on the microglial activation or number of DA neurons was found in healthy mice 
(Fig. 5 B and 6 B) compared to the healthy PBS-treated controls (Fig. 5 A and 6 A, 
respectively) suggesting absence of neurotoxic effects of exosomal carriers in the brain. This 
result was confirmed in in vitro model of primary cortical or DA neurons isolated from 
mouse pups. Thus, a 48-hour exposure of primary neurons to exosomes released from 
macrophages did not affect neuronal survival (Supplemental Fig. S3). Overall, these results 
demonstrate that exosomal formulations of catalase may be useful for PD therapies.
3.6 Co-localization of exosomes with various types of cells in the brain
To assess, which cell type in the brain accumulates exosomes, brain slides were co-stained 
with different cell markers (Fig. 7). Interesting, exosomes were mostly co-localized with 
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neurons, microglia and partially with endothelial cells (Fig. 7). Noteworthy, along with 
distinct endosomal compartments filled with exosomes, a diffuse exosomal staining was 
evident throughout all brain tissues. It is likely the exosome-mediated delivery of catalase to 
activated microglia, astrocytes, and neurons in the inflamed brain may result in ROS 
degradation and neuroprotection in PD patients.
4. DISCUSSION
Currently, there are no treatments that halt or reverse the course of PD, and only palliative 
therapies, such as replacement strategies for missing neurotransmitters, exist. The inability 
of most potent therapeutics, and especially therapeutic proteins, to cross the BBB following 
systemic administration dictates the necessity to develop unconventional, clinically 
applicable drug delivery systems. In this respect, biocompatible vehicles, such as exosomes, 
may help to solve this challenging task. Recent findings indicate that communications 
mediated via exosomes is a common mechanism in the CNS [73]. Therefore, several 
investigations suggested harnessing this natural mechanism of protein and genetic material 
transfer for the delivery of different therapeutics [20, 33-39, 74].
Oxidative stress has long been implicated in the process of neurodegeneration seen in 
Parkinson’s patients. Indeed, the pathogenesis of PD is associated with a lack of the natural 
antioxidants catalase, glutathione and superoxide dismutase in the midbrain region, 
specifically, in the SNpc [75]. It was demonstrated that cells of the immune system, and 
particularly microglia, release pro-inflammatory cytokines in response to different stress 
conditions [76] leading to neuronal demise [77]. Antioxidants can inhibit inflammatory 
responses and protect dopaminergic neurons as reported in laboratory and animal models of 
PD [78-84]. In particular, catalase, one of the most efficient antioxidants found in nature, 
has been shown to rescue primary cerebellar granule cells in in vitro models of PD [85, 86]. 
Several clinical studies have assessed the therapeutic efficacy of low molecular antioxidants 
for PD therapy. Unfortunately, the results of these investigations have been disappointing 
[87] due to the drug poor pharmacokinetics and inability to penetrate the BBB. Thus, the 
development of novel approaches for brain delivery of antioxidants, and in particular redox 
enzymes, is of utmost importance.
We report here the development of a new exosomal-based technology for catalase CNS 
delivery to treat PD. Catalase is a large protein (MW 240 K) that is susceptible to 
deactivation and rapid degradation. Therefore, different techniques for catalase loading into 
exosomes were evaluated: incubation at RT with or without saponin permeabilization, 
freeze/thaw cycles, sonication, or extrusion. Our data indicate the size, morphology, loading 
efficiency, and stability of exoCAT formulations strongly depended on the method of 
preparation. Thus, the extensive reformation and reshaping of exosomes upon sonication and 
extrusion enabled catalase diffusion across relatively tight and highly structured lipid 
bilayers and resulted in the high loading efficiency of exosomal carriers. Notably, these 
approaches for incorporation into exosomes are not specific only for proteins, but can be 
applied to other therapeutic and imaging agents. Thus, TEM studies indicated that a 
substantial amount of gold nanoparticles with the diameter (10.3 ± 1.2 nm) can be also 
incorporated/associated with exosomes by sonication (Supplemental Fig. S4). Interesting, 
Haney et al. Page 15













similar to the sonicated exoCAT (Fig. 1D), nanoparticles-loaded exosomes showed non-
spherical morphology with a variety of shapes (Supplemental Fig. S4). Indeed, it should be 
taken into consideration that the disruption of the exosomes integrity during sonication or 
extrusion procedures may alter their immune-privileged status, and therefore, make them 
visible for the MPS. We will investigate all benefits and disadvantages of these 
manipulations in subsequent studies.
Noteworthy, saponin treatment also increased loading of catalase into exosomes. Saponin is 
the efficient permeabilization agent for cellular plasma membranes [88]. We hypothesized 
that similar to the whole cells, saponin may selectively remove membrane-bound cholesterol 
of exosomes, creating holes/pores in the exosomal lipid bilayers and therefore, promoting 
catalase incorporation. Overall, exoCAT obtained by sonication and extrusion, as well as 
saponin treatment showed the high loading efficiency, preservation of catalase enzymatic 
activity against proteases degradation, and prolonged and sustained release.
Regarding the delivery of incorporated therapeutics to the target cells, this study 
demonstrated the extraordinary ability of exosomes to interact with target cells and deliver 
their “payload” into neighboring neurons. Confocal images revealed fluorescently-labeled 
exosomes were adhering and overflow neuronal cells in abundance. Indeed, comprising of 
cellular membranes exosomes should have an exceptional ability to interact with target cells. 
Furthermore, exosomal surface is rich with tetraspanins and integrins [24, 31, 89] that 
enable the efficient attachment to the plasma membrane of target cells. As a result, 
exosomes accumulated in considerably greater levels in PC12 cells than PLGA 
nanoparticles that have been used as common nanocarriers for PD therapy [90] or liposomes 
[71, 91]. Interesting, the accumulation levels varied for different exosomal preparations. In 
particular, sonicated exosomes showed the greatest uptake in neurons compared to 
exosomes incubated at RT, or aggregates obtained by freeze/thaw cycles. We hypothesized 
that a reorganization of exosomes upon sonication may alter the content of surface proteins 
as well as organization of lipid bilayers that resulted in the increased exosomal interactions 
with cellular membranes of target cells. Obviously, this effect may play a positive role and 
overpower negative effects of decreased uniformity and increased visibility of exosomal 
carriers for the cells of immune system mentioned above.
Concerning the antioxidant activity, exoCAT formulations showed the efficient ROS 
deactivation and significant neuroprotective effects against oxidative stress in vitro. In 
accordance with the loading efficiency, exoCAT obtained by sonication and extrusion 
provided the most potent neuroprotection. We reported earlier that exosomes secreted from 
preloaded with nanoformulated catalase macrophages were accumulated in adjacent cells 
diffusing broadly throughout the cytoplasm and avoiding degradation in lysosomes [43]. 
This mechanism enabled the drug to reach different intracellular compartments, such as 
mitochondria, and endoplasmic reticulum, and produce potent therapeutic effects [43]. We 
speculated that the same favorable intracellular localization of exoCAT may support the 
superior antioxidant and protective activity of exoCAT in neurons. Further investigations 
will reveal mechanism and intracellular trafficking of different exosomal formulations in 
target cells.
Haney et al. Page 16













The intranasal administration provides two main routes for the CNS drug delivery: a) 
transport across the single epithelial cell layer directly to the systemic blood circulation 
without first-pass hepatic and intestinal metabolism; and b) transport along the olfactory 
nerve cells, when drug can bypass the BBB and enter the brain directly. Furthermore, this 
route is attractive due to the possibility of non-invasive multiple treatments with high patient 
compliancy. Interesting, some investigators hypothesized that PD have its origin in the bulbs 
olfactory [92]. Subsequently, it could spread, ascending cell-by-cell through brainstem, 
midbrain, and other regions of the brain, and finally result in PD. Therefore, we reasoned 
that intranasal administration of exoCAT may work the same way delivering therapeutic 
catalase to the affected brain areas. We report here that intranasally administered exosomes 
diffused through the mouse brain, localizing predominantly in the cerebral frontal cortex, 
central sulcus, and cerebellum. This result is consistent with previously reported findings 
regarding the intranasal administration of exosomes loaded with anti-inflammatory drug, 
curcumin [36].
The most important finding of our investigation is that selected exoCAT formulations 
significantly decreased brain inflammation and increased neuronal survival in a PD mouse 
model. The mechanism of these effects is yet to be uncovered. We hypothesized the 
encapsulation of catalase into exosomes may preserve catalase enzymatic activity, prolong 
the blood circulation time, reduce immunogenicity, and improve its interaction with 
epithelial cells, thus improving drug transport and therapeutic effects in PD. Here, we 
investigated two exosomal formulations that were obtained by saponin treatment, and 
sonication. These formulations were chosen as the most efficient ones that can provide high 
loading and sustained drug release. In addition, we evaluated, whether the reformation of 
exosomes upon sonication affected their therapeutic efficacy in vivo. We demonstrated that 
both formulations significantly decreased neuroinflammation and provided potent 
neuroprotection in 6-OHDA mouse model. Furthermore, catalase-loaded exosomes obtained 
by permeabilization with saponin have superior therapeutic effects than those obtained by 
sonication. It is likely that exoCAT obtained by permeabilization with saponin might have 
better uniformity in their surface morphology presumably with the intact membrane 
proteins. This may lead to a lower visibility for RES and clearance by macrophages. Overall, 
successful development of exosome-mediated delivery of catalase could lead to a viable 
therapy for patients with PD.
In clinical settings, different approaches may be applied to introduce exosomal-based drug 
delivery systems (Fig. 8). First, exosomal carriers harvested from peripheral blood 
monocytes by apheresis will be loaded with a therapeutic agent and readministered back into 
the patient. As an alternative approach, stem cells may be harvested from bone marrow, 
propagated in culture to obtain specific cell types, or even subtypes, and then released naïve 
exosomes will be loaded with a therapeutic agent. Although this approach would require a 
more invasive procedure, a significant amount as well as storage of well-characterized 
exosomal carriers will be possible [93]. Noteworthy, exosomes can be concentrated, 
lyophilized, and reconstituted in water solutions, as this study demonstrated. This will allow 
scalability, standardization, and consistency of manufacturing different lots of exososomal 
drug formulations, when a considerable amount and long-turn storage of exosomes might be 
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required. Finally, a library of various types of exosomal carriers for different drug 
formulations could be developed in future and stored in stock for emergency situations.
Also of note, further tailoring exosomes can provide biologically-active carriers that may be 
modified in accordance to the disease and produce cytotoxic (for a cancer treatment) or 
neuroprotective (for the treatment of neurodegenerative disorders) effects enhancing the 
therapeutic outcomes. Thus, drug-loaded exosomes may well serve as a next generation drug 
delivery mechanism that combines nanoparticle size with non-cytotoxic effects, a high drug 
carrying capacity, and a low immunogenic profile.
5. CONCLUSION
This work demonstrates that exosomes are the exceptionally potent carriers for therapeutic 
protein, catalase. We developed an efficient method of the drug loading into exosomes 
without significantly altering their structure, and showed that exosomes loaded with catalase 
efficiently accumulate in neurons and microglial cells in the brain and produce a potent 
neuroprotective effect. These findings indicate that an exosomal based formulations could 
be a valuable tool in the future for the therapy of neurodegenerative disorders. Of course, the 
complexity of these interventions is challenging, yet they promise an unparalleled efficacy 
in the treatment of many life-threatening conditions, including those lacking effective 
pharmacotherapy. Moreover, a positive outcome would also suggest the more general 
applicability of this innovative approach for delivering therapeutics to the central nervous 
system (CNS) and beyond.
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Figure 1. Characterization of exoCAT
Exosomes released from Raw 264.7 macrophages were loaded with catalase by different 
techniques and examined by: (A) western blot, (B) catalase 10 enzymatic activity; and (C) 
catalase release. ExoCAT morphology was examined by AFM (D).
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Figure 2. Preservation of catalase enzymatic activity in exoCAT
ExoCAT obtained by sonication demonstrated the best protection of catalase.
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Figure 3. Accumulation of exoCAT in PC12 cells, and therapeutic effects of exoCAT in in vitro 
models of oxidative stress
The exoCAT uptake in PC12 cells was examined by spectrofluorimetry (A), and confocal 
microscopy (B). The bar: 20 µm. The neuroprotection by exoCAT formulations was 
evaluated in the cell pre-incubated with 6-OHDA (C); (1) catalase, (2) empty exosomes, 
catalase loaded into exosomes by: (3) incubation at RT, (4) saponin permeabilization, (5) 
freeze/thaw cycles, (6) sonication, (7) extrusion. The ability to decrease levels of ROS 
produced in activated macrophages (pre-incubated with LPS and TNF-α) by exoCAT was 
evaluated by Ampex Red assay in vitro (D).
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Figure 4. Biodistribution of DIL-labeled exosomes in mouse brain
Exosomes were administered to mice with 6-OHDA-induced brain inflammation through: 
intranasal (A, B), or intravenous (C) routs; and compared to PBS-injected controls (D). The 
bar: 40 µm.
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Figure 5. Anti-inflammatory effects of exoCAT in PD mouse model
The intranasal administration of exoCAT significantly decreased microglial activation (D, 
E) in 6-OHDA-intoxicated mice compared to those intoxicated with 6-OHDA and then 
treated with PBS (C). Catalase alone did not decrease inflammation in PD mice (F). Empty 
exosomes did not alter the microglial status in healthy animals (B) compared to healthy 
controls (A). The anti-inflammatory effects of the described exosomal formulations were 
quantified by the amount of activated microglial cells (G).
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Figure 6. Neuroprotective effects of exoCAT in PD mouse model
The i.n. administration of exoCAT protected DA neurons (D, E) in 6-OHDA-intoxicated 
mice compared to those intoxicated with 6-OHDA and then treated with PBS (C). Catalase 
alone was not efficient in this model (F). Empty exosomes did not affect the number of DA 
neurons in healthy animals (B) compared to healthy controls (A) indicating the absence of 
cytotoxic effects of the exosomal carriers. The neuroprotective effects of the described 
exosomal formulations were quantified by the amount of DA neurons in the SNpc (G).
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Figure 7. Co-localization of exosomes with different cells in the mouse brain with inflammation
Exosomes released by BMM were labeled with DIL (red). C57BL/6 mice were intoxicated 
with 6-OHDA, and then i.n. injected with fluorescently-labeled exosomes. Four hours later, 
mice were sacrificed, perfused, and brain slides were subjected for confocal examinations. 
Brain slides were stained with antibodies to different cell types and then secondary ab 594 
(green). Nucleus was stained with DAPI (blue). Bar: 10 µm.
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Figure 8. The flow of exoCAT formulations in clinic
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Table 1





Catalase alone 9.5 ± 0.1 0.10 n/a
exosomes alone 100.5 ± 13.5 0.20 99.5 ± 11.2
exoCAT, mixture 108.0 ± 14.3 (ns) 0.35 100 ± 16.3 (ns)
exoCAT, mixture & saponin 110.5 ± 23.1 (ns) 0.35 111 ± 7.8 (ns)
exosomes, freeze/thaw 147.0 ± 10.0 (*) 0.48 125 ± 17 (*)
exoCAT, freeze/thaw 158.0 ± 11.0 (*) 0.48 130 ± 11 (*)
exosomes, sonicated 179.0 ± 10.6 (*) 0.30 150 ± 8.2 (*)
exoCAT, sonicated 183.7 ± 13.8 (**) 0.25 162.4 ± 6.1 (**)
exosomes, extruded 134.0 ± 7.5 (*) 0.25 130 ± 7.5 (*)
exoCAT, extruded 154.8 ± 11.0 (*) 0.29 149.4 ± 3.3 (*)
a
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